It is well documented that PELP1 expression is an independent prognostic predictor of shorter breast cancer–specific survival and disease-free interval [18], and PELP1 dysregulation contributes to BC therapy resistance [19, 20]. The gene discussed is PELP1; the disease is breast carcinoma.